{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:43:27Z","timestamp":1794865407357,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NUW Alliance Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr Metab (Lond)"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dietary therapy, specifically for weight loss, is currently considered first-line therapy for metabolic-associated steatotic liver disease (MASLD). However, increasing recognition of the role of the gut-liver axis in MASLD highlights potential for microbiota-modulating dietary therapy to improve outcomes. This study aimed to explore dietary variables relevant to gut microbiota in MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-five adults with MASLD and 25 healthy controls were recruited using a retrospective case-control design and characterised using 3-day dietary intake records, clinical markers, and shotgun metagenomic sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MASLD participants consumed less dietary fibre (p\u2009=\u2009&lt;\u20090.01), very long chain omega-3 fatty acids (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), nuts and seeds (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), whole grains (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and vegetables (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). Participants with MASLD had lower abundance of\n                      <jats:italic>Alistipes senegalensis<\/jats:italic>\n                      (\n                      <jats:italic>r<\/jats:italic>\n                      =-0.01,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04),\n                      <jats:italic>Coprococcus eutactus<\/jats:italic>\n                      (\n                      <jats:italic>r<\/jats:italic>\n                      =-0.07,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006),\n                      <jats:italic>Faecalibacterium<\/jats:italic>\n                      (\n                      <jats:italic>r<\/jats:italic>\n                      =-0.02,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and higher abundance of\n                      <jats:italic>Ruminococcus torques<\/jats:italic>\n                      (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.04,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), and less expression of functional pathways associated with ethanol production, methionine, folate and branched-chain amino acid metabolism. Bacterial species and functional pathways more abundant in MASLD were positively associated with intake of added sugars and saturated fat, and negatively associated with unsaturated fatty acid and dietary fibre intake.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Microbiota characteristics differ between individuals with and without MASLD, and this is influenced by dietary intake. Future translation-focused research investigating dietary interventions and the gut-liver-axis in MASLD are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12986-025-00939-8","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T01:53:48Z","timestamp":1766454828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inverse associations between Mediterranean diet constituents and the gut microbiota in metabolic-associated steatotic liver disease (MASLD): a case-control study"],"prefix":"10.1186","volume":"23","author":[{"given":"Georgina M.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Hoedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerith","family":"Duncanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lay","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Prakoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Talley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor J.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"47","key":"939_CR1","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","volume":"23","author":"BJ Perumpail","year":"2017","unstructured":"Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263\u201376. https:\/\/doi.org\/10.3748\/wjg.v23.i47.8263.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"939_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322. https:\/\/doi.org\/10.1038\/s41591-018-0104-9.","journal-title":"Nat Med"},{"issue":"1","key":"939_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328\u201357. https:\/\/doi.org\/10.1002\/hep.29367.","journal-title":"Hepatology"},{"issue":"1","key":"939_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/jgh.13857","volume":"33","author":"VW-S Wong","year":"2018","unstructured":"Wong VW-S, Chan W-K, Chitturi S, et al. Asia\u2013Pacific working party on Non-alcoholic fatty liver disease guidelines 2017\u2014Part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70\u201385. https:\/\/doi.org\/10.1111\/jgh.13857.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"939_CR5","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"key":"939_CR6","doi-asserted-by":"publisher","first-page":"m4747","DOI":"10.1136\/bmj.m4747","volume":"372","author":"ML Petroni","year":"2021","unstructured":"Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease. BMJ. 2021;372:m4747. https:\/\/doi.org\/10.1136\/bmj.m4747.","journal-title":"BMJ"},{"key":"939_CR7","doi-asserted-by":"crossref","unstructured":"Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci. 2021;22(5)10.3390\/ijms22052350.","DOI":"10.3390\/ijms22052350"},{"issue":"5","key":"939_CR8","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/hep.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835. https:\/\/doi.org\/10.1097\/hep.0000000000000323.","journal-title":"Hepatology"},{"issue":"6","key":"939_CR9","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.cgh.2021.11.026","volume":"21","author":"E Tsompanaki","year":"2023","unstructured":"Tsompanaki E, Thanapirom K, Papatheodoridi M, Parikh P, Chotai de Lima Y, Tsochatzis EA. Systematic review and Meta-analysis: the role of diet in the development of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21(6):1462\u2013e14741424. https:\/\/doi.org\/10.1016\/j.cgh.2021.11.026.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"939_CR10","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.clnu.2022.06.037","volume":"41","author":"L Haigh","year":"2022","unstructured":"Haigh L, Kirk C, El Gendy K, et al. The effectiveness and acceptability of mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis. Clin Nutr. 2022;41(9):1913\u201331. https:\/\/doi.org\/10.1016\/j.clnu.2022.06.037.","journal-title":"Clin Nutr"},{"issue":"4","key":"939_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ajcnut.2023.02.008","volume":"117","author":"X Feng","year":"2023","unstructured":"Feng X, Lin Y, Zhuo S, et al. Treatment of obesity and metabolic-associated fatty liver disease with a diet or Orlistat: A randomized controlled trial. Am J Clin Nutr. 2023;117(4):691\u2013700. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.02.008.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"939_CR12","doi-asserted-by":"publisher","first-page":"bmjdrc101136","DOI":"10.1136\/bmjdrc-2020-001342","volume":"8","author":"G Della Pepa","year":"2020","unstructured":"Della Pepa G, Vetrani C, Brancato V, et al. Effects of a multifactorial ecosustainable isocaloric diet on liver fat in patients with type 2 diabetes: randomized clinical trial. BMJ Open Diabetes Res Care. 2020;8(1):bmjdrc101136\u20132020.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"939_CR13","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","volume":"70","author":"AY Meir","year":"2021","unstructured":"Meir AY, Rinott E, Tsaban G, et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut. 2021;70(11):2085\u201395. https:\/\/doi.org\/10.1136\/gutjnl-2020-323106.","journal-title":"Gut"},{"issue":"3","key":"939_CR14","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ajcnut.2023.11.013","volume":"119","author":"YC Chooi","year":"2024","unstructured":"Chooi YC, Zhang QA, Magkos F, et al. Effect of an Asian-adapted mediterranean diet and Pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. Am J Clin Nutr. 2024;119(3):788\u201399. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.11.013.","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"939_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/nu9070667","volume":"9","author":"I Cantero","year":"2017","unstructured":"Cantero I, Abete I, Monreal JI, Martinez JA, Zulet MA. Fruit Fiber consumption specifically improves liver health status in obese subjects under energy restriction. Nutrients. 2017;9(7):667.","journal-title":"Nutrients"},{"key":"939_CR16","doi-asserted-by":"crossref","unstructured":"Chen VL, Du X, Oliveri A et al. Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort. J Hepatol. 2024;10.1016\/j.jhep.2024.03.045.","DOI":"10.1016\/j.jhep.2024.03.045"},{"issue":"1","key":"939_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12944-024-02094-0","volume":"23","author":"M Schepp","year":"2024","unstructured":"Schepp M, Freuer D, Wawro N, et al. Association of the habitual dietary intake with the fatty liver index and effect modification by metabotypes in the population-based KORA-Fit study. Lipids Health Dis. 2024;23(1):99. https:\/\/doi.org\/10.1186\/s12944-024-02094-0.","journal-title":"Lipids Health Dis"},{"key":"939_CR18","doi-asserted-by":"crossref","unstructured":"Guo W, Ge X, Lu J et al. Diet and risk of non-alcoholic fatty liver disease, cirrhosis, and liver cancer: a large prospective cohort study in UK Biobank. Nutrients. 2022;14(24)10.3390\/nu14245335.","DOI":"10.3390\/nu14245335"},{"key":"939_CR19","doi-asserted-by":"crossref","unstructured":"Tian T, Zhang J, Xie W et al. Dietary Quality and Relationships with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among United States Adults, Results from NHANES 2017\u20132018. Nutrients. 2022;14(21)10.3390\/nu14214505.","DOI":"10.3390\/nu14214505"},{"issue":"6","key":"939_CR20","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1002\/hep.30967","volume":"71","author":"M Noureddin","year":"2020","unstructured":"Noureddin M, Zelber-Sagi S, Wilkens LR, et al. Diet associations with nonalcoholic fatty liver disease in an ethnically diverse population: the multiethnic cohort. Hepatology. 2020;71(6):1940\u201352. https:\/\/doi.org\/10.1002\/hep.30967.","journal-title":"Hepatology"},{"issue":"8","key":"939_CR21","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00394-014-0679-y","volume":"53","author":"M Georgoulis","year":"2014","unstructured":"Georgoulis M, Kontogianni MD, Tileli N, et al. The impact of cereal grain consumption on the development and severity of non-alcoholic fatty liver disease. Eur J Nutr. 2014;53(8):1727\u201335. https:\/\/doi.org\/10.1007\/s00394-014-0679-y.","journal-title":"Eur J Nutr"},{"key":"939_CR22","doi-asserted-by":"publisher","first-page":"1225946","DOI":"10.3389\/fnut.2023.1225946","volume":"10","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Zhang X, Yi D, et al. Mediterranean diet affects the metabolic outcome of metabolic dysfunction-associated fatty liver disease. Front Nutr. 2023;10:1225946. https:\/\/doi.org\/10.3389\/fnut.2023.1225946.","journal-title":"Front Nutr"},{"issue":"3","key":"939_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/advances\/nmy013","volume":"9","author":"MA Bailey","year":"2018","unstructured":"Bailey MA, Holscher HD. Microbiome-Mediated effects of the mediterranean diet on inflammation. Adv Nutr. 2018;9(3):193\u2013206. https:\/\/doi.org\/10.1093\/advances\/nmy013.","journal-title":"Adv Nutr"},{"issue":"12","key":"939_CR24","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.cmet.2021.09.004","volume":"33","author":"MA Febbraio","year":"2021","unstructured":"Febbraio MA, Karin M. Sweet death: Fructose as a metabolic toxin that targets the gut-liver axis. Cell Metabol. 2021;33(12):2316\u201328. https:\/\/doi.org\/10.1016\/j.cmet.2021.09.004.","journal-title":"Cell Metabol"},{"issue":"7","key":"939_CR25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s42255-020-0222-9","volume":"2","author":"C Jang","year":"2020","unstructured":"Jang C, Wada S, Yang S, et al. The small intestine shields the liver from fructose-induced steatosis. Nat Metabolism. 2020;2(7):586\u201393. https:\/\/doi.org\/10.1038\/s42255-020-0222-9.","journal-title":"Nat Metabolism"},{"issue":"10","key":"939_CR26","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s42255-020-0261-2","volume":"2","author":"J Todoric","year":"2020","unstructured":"Todoric J, Di Caro G, Reibe S, et al. Fructose stimulated de Novo lipogenesis is promoted by inflammation. Nat Metab. 2020;2(10):1034\u201345. https:\/\/doi.org\/10.1038\/s42255-020-0261-2.","journal-title":"Nat Metab"},{"issue":"8","key":"939_CR27","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.2337\/dc18-0071","volume":"41","author":"PK Luukkonen","year":"2018","unstructured":"Luukkonen PK, S\u00e4devirta S, Zhou Y, et al. Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars. Diabetes Care. 2018;41(8):1732\u20139. https:\/\/doi.org\/10.2337\/dc18-0071.","journal-title":"Diabetes Care"},{"issue":"11","key":"939_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","volume":"21","author":"CL Hsu","year":"2023","unstructured":"Hsu CL, Schnabl B. The gut\u2013liver axis and gut microbiota in health and liver disease. Nat Rev Microbiol. 2023;21(11):719\u201333. https:\/\/doi.org\/10.1038\/s41579-023-00904-3.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"939_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12944-021-01440-w","volume":"20","author":"F Li","year":"2021","unstructured":"Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis. Lipids Health Dis. 2021;20(1):22. https:\/\/doi.org\/10.1186\/s12944-021-01440-w.","journal-title":"Lipids Health Dis"},{"issue":"12","key":"939_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","volume":"18","author":"M Masoodi","year":"2021","unstructured":"Masoodi M, Gastaldelli A, Hy\u00f6tyl\u00e4inen T, et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol. 2021;18(12):835\u201356. https:\/\/doi.org\/10.1038\/s41575-021-00502-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"939_CR31","unstructured":"What are the serve sizes for the Xyris food groups?. Accessed 5\/8\/2022. https:\/\/support.foodworks.online\/hc\/en-au\/articles\/360003926475-What-are-the-serve-sizes-for-the-Xyris-food-groups"},{"key":"939_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jfca.2016.05.005","volume":"50","author":"LM Galea","year":"2016","unstructured":"Galea LM, Dalton SMC, Beck EJ, Cashman CJ, Probst YC. Update of a database for Estimation of whole grain content of foods in Australia. J Food Compos Anal. 2016;50:23\u20139. https:\/\/doi.org\/10.1016\/j.jfca.2016.05.005.","journal-title":"J Food Compos Anal"},{"key":"939_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jfca.2017.10.004","volume":"66","author":"EM Barrett","year":"2018","unstructured":"Barrett EM, Probst YC, Beck EJ. Creation of a database for the Estimation of cereal fibre content in foods. J Food Compos Anal. 2018;66:1\u20136. https:\/\/doi.org\/10.1016\/j.jfca.2017.10.004.","journal-title":"J Food Compos Anal"},{"issue":"6","key":"939_CR34","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325. https:\/\/doi.org\/10.1002\/hep.21178.","journal-title":"Hepatology"},{"issue":"4","key":"939_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1478-3231.2009.02192.x","volume":"30","author":"BK Kim","year":"2010","unstructured":"Kim BK, Kim DY, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30(4):546\u201353. https:\/\/doi.org\/10.1111\/j.1478-3231.2009.02192.x.","journal-title":"Liver Int"},{"issue":"5","key":"939_CR36","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/flgastro-2021-102064","volume":"13","author":"AJ Archer","year":"2022","unstructured":"Archer AJ, Belfield KJ, Orr JG, Gordon FH, Abeysekera KW. EASL clinical practice guidelines: non-invasive liver tests for evaluation of liver disease severity and prognosis. Frontline Gastroenterol. 2022;13(5):436\u20139. https:\/\/doi.org\/10.1136\/flgastro-2021-102064.","journal-title":"Frontline Gastroenterol"},{"issue":"4","key":"939_CR37","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846\u201354. https:\/\/doi.org\/10.1002\/hep.21496.","journal-title":"Hepatology"},{"issue":"8","key":"939_CR38","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3748\/wjg.v19.i8.1219","volume":"19","author":"S Treeprasertsuk","year":"2013","unstructured":"Treeprasertsuk S, Bj\u00f6rnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013;19(8):1219\u201329. https:\/\/doi.org\/10.3748\/wjg.v19.i8.1219.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"939_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","volume":"41","author":"J Lee","year":"2021","unstructured":"Lee J, Vali Y, Boursier J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int. 2021;41(2):261\u201370. https:\/\/doi.org\/10.1111\/liv.14669.","journal-title":"Liver Int"},{"issue":"6","key":"939_CR40","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW-S, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hep Intl. 2020;14(6):889\u2013919. https:\/\/doi.org\/10.1007\/s12072-020-10094-2.","journal-title":"Hep Intl"},{"issue":"03","key":"939_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1055\/s-0041-1723751","volume":"41","author":"T Kawaguchi","year":"2021","unstructured":"Kawaguchi T, Charlton M, Kawaguchi A, et al. Effects of mediterranean diet in patients with nonalcoholic fatty liver disease: A systematic review, Meta-Analysis, and Meta-Regression analysis of randomized controlled trials. Semin Liver Dis. 2021;41(03):225\u201334. https:\/\/doi.org\/10.1055\/s-0041-1723751.","journal-title":"Semin Liver Dis"},{"issue":"4","key":"939_CR42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s1499-3872(17)60019-5","volume":"16","author":"F Shen","year":"2017","unstructured":"Shen F, Zheng RD, Sun XQ, Ding WJ, Wang XY, Fan JG. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2017;16(4):375\u201381. https:\/\/doi.org\/10.1016\/s1499-3872(17)60019-5.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"7","key":"939_CR43","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1136\/gutjnl-2020-322670","volume":"70","author":"LA Bolte","year":"2021","unstructured":"Bolte LA, Vich Vila A, Imhann F, et al. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut Microbiome. Gut. 2021;70(7):1287\u201398. https:\/\/doi.org\/10.1136\/gutjnl-2020-322670.","journal-title":"Gut"},{"issue":"1","key":"939_CR44","doi-asserted-by":"publisher","first-page":"1888673","DOI":"10.1080\/19490976.2021.1888673","volume":"13","author":"MO Ruuskanen","year":"2021","unstructured":"Ruuskanen MO, \u00c5berg F, M\u00e4nnist\u00f6 V, et al. Links between gut Microbiome composition and fatty liver disease in a large population sample. Gut Microbes. 2021;13(1):1888673. https:\/\/doi.org\/10.1080\/19490976.2021.1888673.","journal-title":"Gut Microbes"},{"issue":"1","key":"939_CR45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41467-023-35861-1","volume":"14","author":"M Yang","year":"2023","unstructured":"Yang M, Qi X, Li N, et al. Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. Nat Commun. 2023;14(1):228. https:\/\/doi.org\/10.1038\/s41467-023-35861-1.","journal-title":"Nat Commun"},{"issue":"3","key":"939_CR46","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00394-023-03308-4","volume":"63","author":"S Tagliamonte","year":"2024","unstructured":"Tagliamonte S, Puhlmann ML, De Filippis F, Guerville M, Ercolini D, Vitaglione P. Relationships between diet and gut Microbiome in an Italian and Dutch cohort: does the dietary protein to fiber ratio play a role? Eur J Nutr. 2024;63(3):741\u201350. https:\/\/doi.org\/10.1007\/s00394-023-03308-4.","journal-title":"Eur J Nutr"},{"issue":"7","key":"939_CR47","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/gutjnl-2019-320438","volume":"69","author":"V Meslier","year":"2020","unstructured":"Meslier V, Laiola M, Roager HM, et al. Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut Microbiome and metabolome independently of energy intake. Gut. 2020;69(7):1258. https:\/\/doi.org\/10.1136\/gutjnl-2019-320438.","journal-title":"Gut"},{"issue":"11","key":"939_CR48","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1017\/S0007114524000631","volume":"131","author":"R Ma","year":"2024","unstructured":"Ma R, Shi G, Li Y, Shi H. Trimethylamine N-oxide, choline and its metabolites are associated with the risk of non-alcoholic fatty liver disease. Br J Nutr. 2024;131(11):1915\u201323. https:\/\/doi.org\/10.1017\/S0007114524000631.","journal-title":"Br J Nutr"},{"key":"939_CR49","doi-asserted-by":"crossref","unstructured":"Theofilis P, Vordoni A, Kalaitzidis RG. Trimethylamine N-Oxide Levels in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Metabolites. 2022;12(12)10.3390\/metabo12121243.","DOI":"10.3390\/metabo12121243"},{"issue":"5","key":"939_CR50","doi-asserted-by":"publisher","first-page":"101016jheliyon2","DOI":"10.1016\/j.heliyon.2024.e26991","volume":"10","author":"X Li","year":"2024","unstructured":"Li X, He M, Yi X, et al. Short-chain fatty acids in nonalcoholic fatty liver disease: new prospects for short-chain fatty acids as therapeutic targets. Heliyon. 2024;10(5):101016jheliyon2024e26991.","journal-title":"Heliyon"},{"issue":"10","key":"939_CR51","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","volume":"67","author":"N Jiao","year":"2018","unstructured":"Jiao N, Baker SS, Chapa-Rodriguez A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2018;67(10):1881\u201391. https:\/\/doi.org\/10.1136\/gutjnl-2017-314307.","journal-title":"Gut"},{"issue":"3","key":"939_CR52","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3945\/ajcn.114.086314","volume":"100","author":"M Chung","year":"2014","unstructured":"Chung M, Ma J, Patel K, Berger S, Lau J, Lichtenstein AH. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis1,2,3,4. Am J Clin Nutr. 2014;100(3):833\u201349. https:\/\/doi.org\/10.3945\/ajcn.114.086314.","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"939_CR53","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/s41591-022-02016-6","volume":"28","author":"AS Meijnikman","year":"2022","unstructured":"Meijnikman AS, Davids M, Herrema H, et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nat Med. 2022;28(10):2100\u20136. https:\/\/doi.org\/10.1038\/s41591-022-02016-6.","journal-title":"Nat Med"},{"issue":"4","key":"939_CR54","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cmet.2019.08.018","volume":"30","author":"J Yuan","year":"2019","unstructured":"Yuan J, Chen C, Cui J, et al. Fatty liver disease caused by High-Alcohol-Producing\u2009<\u2009em\u2009>\u2009Klebsiella pneumoniae. Cell Metabol. 2019;30(4):675\u2013e688677. https:\/\/doi.org\/10.1016\/j.cmet.2019.08.018.","journal-title":"Cell Metabol"},{"key":"939_CR55","doi-asserted-by":"crossref","unstructured":"Elshaghabee FMF, Bockelmann W, Meske D et al. Ethanol production by selected intestinal microorganisms and lactic acid bacteria growing under different nutritional conditions. Original Research. Frontiers in Microbiology. 2016;710.3389\/fmicb.2016.00047.","DOI":"10.3389\/fmicb.2016.00047"},{"issue":"5","key":"939_CR56","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/jcm9051369","volume":"9","author":"P Iruzubieta","year":"2020","unstructured":"Iruzubieta P, Medina JM, Fern\u00e1ndez-L\u00f3pez R, Crespo J, de la Cruz F. A role for gut Microbiome fermentative pathways in fatty liver disease progression. J Clin Med. 2020;9(5):1369.","journal-title":"J Clin Med"},{"key":"939_CR57","doi-asserted-by":"publisher","unstructured":"Meijnikman AS, Nieuwdorp M, Schnabl B. Endogenous ethanol production in health and disease. Nat Reviews Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1038\/s41575-024-00937-w.","DOI":"10.1038\/s41575-024-00937-w"},{"key":"939_CR58","doi-asserted-by":"publisher","first-page":"920277","DOI":"10.3389\/fmicb.2022.920277","volume":"13","author":"R Zhang","year":"2022","unstructured":"Zhang R, Mu H, Li Z, et al. Oral administration of branched-chain amino acids ameliorates high-fat diet-induced metabolic-associated fatty liver disease via gut microbiota-associated mechanisms. Front Microbiol. 2022;13:920277. https:\/\/doi.org\/10.3389\/fmicb.2022.920277.","journal-title":"Front Microbiol"},{"issue":"9","key":"939_CR59","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","volume":"35","author":"Y Ni","year":"2023","unstructured":"Ni Y, Qian L, Siliceo SL, et al. Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut Microbiome alterations. Cell Metabol. 2023;35(9):1530\u2013e1547. https:\/\/doi.org\/10.1016\/j.cmet.2023.08.002.","journal-title":"Cell Metabol"},{"issue":"1","key":"939_CR60","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13073-022-01015-z","volume":"14","author":"E Rinott","year":"2022","unstructured":"Rinott E, Meir AY, Tsaban G, et al. The effects of the Green-Mediterranean diet on cardiometabolic health are linked to gut Microbiome modifications: a randomized controlled trial. Genome Med. 2022;14(1):29. https:\/\/doi.org\/10.1186\/s13073-022-01015-z.","journal-title":"Genome Med"},{"key":"939_CR61","doi-asserted-by":"publisher","unstructured":"Tsaban G, Yaskolka Meir A, Rinott E et al. The effect of green Mediterranean diet on cardiometabolic risk; a randomised controlled trial. Heart. 2021;107(13):1054\u201361. https:\/\/doi.org\/10.1136\/heartjnl-2020-317802","DOI":"10.1136\/heartjnl-2020-317802"},{"issue":"8","key":"939_CR62","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1002\/hep4.1944","volume":"6","author":"T Testerman","year":"2022","unstructured":"Testerman T, Li Z, Galuppo B, Graf J, Santoro N. Insights from shotgun metagenomics into bacterial species and metabolic pathways associated with NAFLD in obese youth. Hepatol Commun. 2022;6(8):1962\u201374. https:\/\/doi.org\/10.1002\/hep4.1944.","journal-title":"Hepatol Commun"},{"issue":"3","key":"939_CR63","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.chom.2020.01.006","volume":"27","author":"EC Deehan","year":"2020","unstructured":"Deehan EC, Yang C, Perez-Mu\u00f1oz ME, et al. Precision Microbiome modulation with discrete dietary Fiber structures directs Short-Chain fatty acid production. Cell Host Microbe. 2020;27(3):389\u2013e404386. https:\/\/doi.org\/10.1016\/j.chom.2020.01.006.","journal-title":"Cell Host Microbe"},{"issue":"5","key":"939_CR64","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","volume":"17","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Reviews Gastroenterol Hepatol. 2020;17(5):279\u201397. https:\/\/doi.org\/10.1038\/s41575-020-0269-9.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"1","key":"939_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12920-024-01861-3","volume":"17","author":"A Khavandegar","year":"2024","unstructured":"Khavandegar A, Heidarzadeh A, Angoorani P, et al. Adherence to the mediterranean diet can beneficially affect the gut microbiota composition: a systematic review. BMC Med Genom. 2024;17(1):91. https:\/\/doi.org\/10.1186\/s12920-024-01861-3.","journal-title":"BMC Med Genom"},{"issue":"1","key":"939_CR66","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1038\/s41467-023-38778-x","volume":"14","author":"KD Corbin","year":"2023","unstructured":"Corbin KD, Carnero EA, Dirks B, et al. Host-diet-gut Microbiome interactions influence human energy balance: a randomized clinical trial. Nat Commun. 2023;14(1):3161. https:\/\/doi.org\/10.1038\/s41467-023-38778-x.","journal-title":"Nat Commun"},{"issue":"1","key":"939_CR67","doi-asserted-by":"publisher","first-page":"2350785","DOI":"10.1080\/19490976.2024.2350785","volume":"16","author":"K Duncanson","year":"2024","unstructured":"Duncanson K, Williams G, Hoedt EC, Collins CE, Keely S, Talley NJ. Diet-microbiota associations in Gastrointestinal research: a systematic review. Gut Microbes. 2024;16(1):2350785. https:\/\/doi.org\/10.1080\/19490976.2024.2350785.","journal-title":"Gut Microbes"},{"issue":"4","key":"939_CR68","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1055\/s-0037-1608832","volume":"37","author":"A Shah","year":"2017","unstructured":"Shah A, Shanahan E, Macdonald GA, et al. Systematic review and Meta-Analysis: prevalence of small intestinal bacterial overgrowth in chronic liver disease. Semin Liver Dis. 2017;37(4):388\u2013400. https:\/\/doi.org\/10.1055\/s-0037-1608832.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"939_CR69","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.clnu.2018.12.022","volume":"38","author":"M Plauth","year":"2019","unstructured":"Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 2019;38(2):485\u2013521. https:\/\/doi.org\/10.1016\/j.clnu.2018.12.022.","journal-title":"Clin Nutr"},{"issue":"11","key":"939_CR70","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1016\/j.cgh.2022.11.030","volume":"21","author":"J Soppert","year":"2023","unstructured":"Soppert J, Brandt EF, Heussen NM, et al. Blood endotoxin levels as biomarker of nonalcoholic fatty liver disease: A systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21(11):2746\u201358. https:\/\/doi.org\/10.1016\/j.cgh.2022.11.030.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Nutrition &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12986-025-00939-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-025-00939-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-025-00939-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:43:32Z","timestamp":1768484612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12986-025-00939-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1186\/s12986-025-00939-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5635238\/v1","asserted-by":"object"}]},"ISSN":["1743-7075"],"issn-type":[{"value":"1743-7075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical clearance was obtained from the South Western Sydney Ethics Committee (2020\/ETH01641). All participants completed a written consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants consented to publication of data as outlined in participant written consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}